{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T06:51:58Z","timestamp":1778223118551,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:00:00Z","timestamp":1584403200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:00:00Z","timestamp":1584403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00103-020-03120-z","type":"journal-article","created":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T13:02:47Z","timestamp":1584450167000},"page":"506-511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Medikament\u00f6se Pr\u00e4vention von\u00a0kognitiver Verschlechterung und\u00a0Demenz","Pharmacological prevention of cognitive decline and dementia"],"prefix":"10.1007","volume":"63","author":[{"given":"Frank","family":"Jessen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,17]]},"reference":[{"key":"3120_CR1","unstructured":"Statista (2020) Bev\u00f6lkerung \u2013 Zahl der Einwohner in Deutschland nach Altersgruppen am 31. Dezember 2018. https:\/\/de.statista.com\/statistik\/daten\/studie\/1365\/umfrage\/bevoelkerung-deutschlands-nach-altersgruppen\/. Zugegriffen: 11. Jan. 2020"},{"key":"3120_CR2","unstructured":"MetLife Foundation (2011) Alzheimer\u2019s survey. https:\/\/www.metlife.com\/content\/dam\/microsites\/about\/corporate-profile\/alzheimers-2011.pdf. Zugegriffen: 11. Jan. 2020"},{"key":"3120_CR3","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1106668","volume":"366","author":"R Howard","year":"2012","unstructured":"Howard\u00a0R, McShane\u00a0R, Lindesay\u00a0J et al (2012) Donepezil and memantine for moderate-to-severe Alzheimer\u2019s disease. N\u00a0Engl J Med 366:893\u2013903","journal-title":"N Engl J Med"},{"key":"3120_CR4","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert\u00a0MS, DeKosky\u00a0ST, Dickson\u00a0D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the national institute on aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7:270\u2013279","journal-title":"Alzheimers Dement"},{"key":"3120_CR5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1600-0447.2008.01326.x","volume":"119","author":"AJ Mitchell","year":"2009","unstructured":"Mitchell\u00a0AJ, Shiri-Feshki\u00a0M (2009) Rate of progression of mild cognitive impairment to dementia\u2014meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 119:252\u2013265","journal-title":"Acta Psychiatr Scand"},{"key":"3120_CR6","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois\u00a0B, Feldman\u00a0HH, Jacova\u00a0C et al (2014) Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG\u20112 criteria. Lancet Neurol 13:614\u2013629","journal-title":"Lancet Neurol"},{"key":"3120_CR7","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa050151","volume":"352","author":"RC Petersen","year":"2005","unstructured":"Petersen\u00a0RC, Thomas\u00a0RG, Grundman\u00a0M et\u00a0al (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N\u00a0Engl J Med 352:2379\u20132388","journal-title":"N Engl J Med"},{"key":"3120_CR8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3233\/JAD-190546","volume":"71","author":"S Matsunaga","year":"2019","unstructured":"Matsunaga\u00a0S, Fujishiro\u00a0H, Takechi\u00a0H (2019) Efficacy and safety of cholinesterase inhibitors for mild cognitive impairment: a systematic review and meta-analysis. J\u00a0Alzheimers Dis 71:513\u2013523","journal-title":"J Alzheimers Dis"},{"key":"3120_CR9","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.jalz.2014.10.003","volume":"11","author":"B Dubois","year":"2015","unstructured":"Dubois\u00a0B, Chupin\u00a0M, Hampel\u00a0H et\u00a0al (2015) Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer\u2019s disease. Alzheimers Dement 11:1041\u20131049","journal-title":"Alzheimers Dement"},{"key":"3120_CR10","first-page":"CD003154","volume":"3","author":"R McShane","year":"2019","unstructured":"McShane\u00a0R, Westby\u00a0MJ, Roberts\u00a0E et\u00a0al (2019) Memantine for dementia. Cochrane Database Syst Rev 3:CD3154","journal-title":"Cochrane Database Syst Rev"},{"key":"3120_CR11","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway\u00a0S, Sperling\u00a0R, Fox\u00a0NC et al (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N\u00a0Engl J Med 370:322\u2013333","journal-title":"N Engl J Med"},{"key":"3120_CR12","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","volume":"378","author":"LS Honig","year":"2018","unstructured":"Honig\u00a0LS, Vellas\u00a0B, Woodward\u00a0M et\u00a0al (2018) Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease. N\u00a0Engl J Med 378:321\u2013330","journal-title":"N Engl J Med"},{"key":"3120_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","volume":"9","author":"S Ostrowitzki","year":"2017","unstructured":"Ostrowitzki\u00a0S, Lasser\u00a0RA, Dorflinger\u00a0E et\u00a0al (2017) A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease. Alzheimers Res Ther 9:95","journal-title":"Alzheimers Res Ther"},{"key":"3120_CR14","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","volume":"380","author":"MF Egan","year":"2019","unstructured":"Egan\u00a0MF, Kost\u00a0J, Voss\u00a0T et\u00a0al (2019) Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease. N\u00a0Engl J Med 380:1408\u20131420","journal-title":"N Engl J Med"},{"key":"3120_CR15","doi-asserted-by":"publisher","first-page":"228fs13","DOI":"10.1126\/scitranslmed.3007941","volume":"6","author":"RA Sperling","year":"2014","unstructured":"Sperling\u00a0RA, Rentz\u00a0DM, Johnson\u00a0KA et\u00a0al (2014) The A4 study: stopping AD before symptoms begin? Sci Transl Med 6:228fs13","journal-title":"Sci Transl Med"},{"key":"3120_CR16","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.trci.2018.02.002","volume":"4","author":"PN Tariot","year":"2018","unstructured":"Tariot\u00a0PN, Lopera\u00a0F, Langbaum\u00a0JB et al (2018) The Alzheimer\u2019s prevention initiative autosomal-dominant Alzheimer\u2019s disease trial: a study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer\u2019s disease, including a\u00a0placebo-treated noncarrier cohort. Alzheimers Dement (N Y) 4:150\u2013160","journal-title":"Alzheimers Dement (N Y)"},{"key":"3120_CR17","doi-asserted-by":"publisher","first-page":"12861","DOI":"10.1038\/s41598-017-13168-8","volume":"7","author":"S Policicchio","year":"2017","unstructured":"Policicchio\u00a0S, Ahmad\u00a0AN, Powell\u00a0JF, Proitsi\u00a0P (2017) Rheumatoid arthritis and risk for Alzheimer\u2019s disease: a\u00a0systematic review and meta-analysis and a\u00a0Mendelian randomization study. Sci Rep 7:12861","journal-title":"Sci Rep"},{"key":"3120_CR18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3233\/JAD-141506","volume":"44","author":"J Wang","year":"2015","unstructured":"Wang\u00a0J, Tan\u00a0L, Wang\u00a0H\u2011F et al (2015) Anti-inflammatory drugs and risk of Alzheimer\u2019s disease: an updated systematic review and meta-analysis. J\u00a0Alzheimers Dis 44:385\u2013396","journal-title":"J Alzheimers Dis"},{"key":"3120_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s40266-015-0239-z","volume":"32","author":"M Miguel-\u00c1lvarez","year":"2015","unstructured":"Miguel-\u00c1lvarez\u00a0M, Santos-Lozano\u00a0A, Sanchis-Gomar\u00a0F et al (2015) Non-steroidal anti-inflammatory drugs as a\u00a0treatment for Alzheimer\u2019s disease: a systematic review and meta-analysis of treatment effect. Drugs Aging 32:139\u2013147","journal-title":"Drugs Aging"},{"key":"3120_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2174\/156720511795256099","volume":"8","author":"MT Heneka","year":"2011","unstructured":"Heneka\u00a0MT, Kummer\u00a0MP, Weggen\u00a0S et\u00a0al (2011) Molecular mechanisms and therapeutic application of NSAIDs and derived compounds in Alzheimer\u2019s disease. Curr Alzheimer Res 8:115\u2013131","journal-title":"Curr Alzheimer Res"},{"key":"3120_CR21","doi-asserted-by":"publisher","first-page":"e11304","DOI":"10.1097\/MD.0000000000011304","volume":"97","author":"X Zhang","year":"2018","unstructured":"Zhang\u00a0X, Wen\u00a0J, Zhang\u00a0Z (2018) Statins use and risk of dementia. Medicine 97:e11304","journal-title":"Medicine"},{"key":"3120_CR22","first-page":"CD007514","volume":"8","author":"B McGuinness","year":"2014","unstructured":"McGuinness\u00a0B, Craig\u00a0D, Bullock\u00a0R, Malouf\u00a0R, Passmore\u00a0P (2014) Statins for the treatment of dementia. Cochrane Database Syst Rev 8:CD7514","journal-title":"Cochrane Database Syst Rev"},{"key":"3120_CR23","first-page":"CD003160","volume":"1","author":"B McGuinness","year":"2016","unstructured":"McGuinness\u00a0B, Craig\u00a0D, Bullock\u00a0R, Passmore\u00a0P (2016) Statins for the prevention of dementia. Cochrane Database Syst Rev 1:CD3160","journal-title":"Cochrane Database Syst Rev"},{"key":"3120_CR24","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","volume":"390","author":"G Livingston","year":"2017","unstructured":"Livingston\u00a0G, Sommerlad\u00a0A, Orgeta\u00a0V et\u00a0al (2017) Dementia prevention, intervention, and care. Lancet 390:2673\u20132734","journal-title":"Lancet"},{"key":"3120_CR25","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1097\/HJH.0000000000001829","volume":"36","author":"T van Middelaar","year":"2018","unstructured":"van Middelaar\u00a0T, van Vught\u00a0LA, van Gool\u00a0WA et al (2018) Blood pressure-lowering interventions to prevent dementia. J\u00a0Hypertens 36:1780\u20131787","journal-title":"J Hypertens"},{"key":"3120_CR26","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1001\/archinte.162.18.2046","volume":"162","author":"F Forette","year":"2002","unstructured":"Forette\u00a0F, Seux\u00a0M\u2011L, Staessen\u00a0JA et al (2002) The prevention of dementia with antihypertensive treatment: new evidence from the systolic hypertension in europe (Syst-Eur) study. Arch Intern Med 162:2046\u20132052","journal-title":"Arch Intern Med"},{"key":"3120_CR27","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright","year":"2015","unstructured":"SPRINT Research Group, Wright\u00a0JT, Williamson\u00a0JD et al (2015) A randomized trial of intensive versus standard blood-pressure control. N\u00a0Engl J Med 373:2103\u20132116","journal-title":"N Engl J Med"},{"key":"3120_CR28","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/jama.2018.21442","volume":"321","author":"JD Williamson","year":"2019","unstructured":"Williamson\u00a0JD, Pajewski\u00a0NM, Auchus\u00a0AP et\u00a0al (2019) Effect of intensive vs standard blood pressure control on probable dementia. JAMA 321:553\u2013561","journal-title":"JAMA"},{"key":"3120_CR29","first-page":"225","volume":"5","author":"O Scheyer","year":"2018","unstructured":"Scheyer\u00a0O, Rahman\u00a0A, Hristov\u00a0H et\u00a0al (2018) Female sex and alzheimer\u2019s risk: the menopause connection. J\u00a0Prev Alzheimers Dis 5:225\u2013230","journal-title":"J Prev Alzheimers Dis"},{"key":"3120_CR30","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1097\/GME.0000000000001241","volume":"25","author":"No Authors listed","year":"2018","unstructured":"No Authors listed (2018) The 2017 hormone therapy position statement of the north American menopause society. Menopause 25:1362\u20131387","journal-title":"Menopause"},{"key":"3120_CR31","doi-asserted-by":"publisher","first-page":"l665","DOI":"10.1136\/bmj.l665","volume":"364","author":"H Savolainen-Peltonen","year":"2019","unstructured":"Savolainen-Peltonen\u00a0H, Rahkola-Soisalo\u00a0P, Hoti\u00a0F et al (2019) Use of postmenopausal hormone therapy and risk of Alzheimer\u2019s disease in Finland: nationwide case-control study. BMJ 364:l665","journal-title":"BMJ"},{"key":"3120_CR32","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nature01640","volume":"423","author":"CJ Phiel","year":"2003","unstructured":"Phiel\u00a0CJ, Wilson\u00a0CA, Lee\u00a0VM\u2011Y, Klein\u00a0PS (2003) GSK-3\u03b1 regulates production of Alzheimer\u2019s disease amyloid\u2011\u03b2 peptides. Nature 423:435\u2013439","journal-title":"Nature"},{"key":"3120_CR33","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2174\/1567205013666160219112854","volume":"13","author":"OV Forlenza","year":"2016","unstructured":"Forlenza\u00a0OV, Aprahamian\u00a0I, de Paula\u00a0VJ, Hajek\u00a0T (2016) Lithium, a\u00a0therapy for AD: current evidence from clinical trials of neurodegenerative disorders. Curr Alzheimer Res 13:879\u2013886","journal-title":"Curr Alzheimer Res"},{"key":"3120_CR34","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.4088\/JCP.15m10304","volume":"78","author":"C Cheng","year":"2017","unstructured":"Cheng\u00a0C, Zandi\u00a0P, Stuart\u00a0E et\u00a0al (2017) Association between lithium use and risk of Alzheimer\u2019s disease. J\u00a0Clin Psychiatry 78:e139\u201345","journal-title":"J Clin Psychiatry"},{"key":"3120_CR35","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1001\/jamapsychiatry.2017.2362","volume":"74","author":"LV Kessing","year":"2017","unstructured":"Kessing\u00a0LV, Gerds\u00a0TA, Knudsen\u00a0NN et\u00a0al (2017) Association of lithium in drinking water with the incidence of dementia. Jama Psychiatry 74:1005\u20131010","journal-title":"Jama Psychiatry"},{"key":"3120_CR36","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1001\/jama.2008.683","volume":"300","author":"ST DeKosky","year":"2008","unstructured":"DeKosky\u00a0ST, Williamson\u00a0JD, Fitzpatrick\u00a0AL et\u00a0al (2008) Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 300:2253\u20132262","journal-title":"JAMA"},{"key":"3120_CR37","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S1474-4422(12)70206-5","volume":"11","author":"B Vellas","year":"2012","unstructured":"Vellas\u00a0B, Coley\u00a0N, Ousset\u00a0P\u2011J et al (2012) Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer\u2019s disease (GuidAge): a\u00a0randomised placebo-controlled trial. Lancet Neurol 11:851\u2013859","journal-title":"Lancet Neurol"},{"key":"3120_CR38","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3233\/JAD-2012-121189","volume":"31","author":"P Scheltens","year":"2012","unstructured":"Scheltens\u00a0P, Twisk\u00a0JWR, Blesa\u00a0R et\u00a0al (2012) Efficacy of souvenaid in mild alzheimer\u2019s disease: results from a\u00a0randomized, controlled trial. J\u00a0Alzheimers Dis 31:225\u2013236","journal-title":"J Alzheimers Dis"},{"key":"3120_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2009.10.003","volume":"6","author":"P Scheltens","year":"2010","unstructured":"Scheltens\u00a0P, Kamphuis\u00a0PJGH, Verhey\u00a0FRJ et\u00a0al (2010) Efficacy of a\u00a0medical food in mild Alzheimer\u2019s disease: a randomized, controlled trial. Alzheimers Dement 6:1\u201310","journal-title":"Alzheimers Dement"},{"key":"3120_CR40","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/S1474-4422(17)30332-0","volume":"16","author":"H Soininen","year":"2017","unstructured":"Soininen\u00a0H, Solomon\u00a0A, Visser\u00a0PJ et al (2017) 24-month intervention with a\u00a0specific multinutrient in people with prodromal alzheimer\u2019s disease (LipiDidiet): a\u00a0randomised, double-blind, controlled trial. Lancet Neurol 16:965\u2013975","journal-title":"Lancet Neurol"},{"key":"3120_CR41","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/s41582-018-0070-3","volume":"14","author":"M Kivipelto","year":"2018","unstructured":"Kivipelto\u00a0M, Mangialasche\u00a0F, Ngandu\u00a0T (2018) Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat Rev Neurol 14:653\u2013666","journal-title":"Nat Rev Neurol"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-020-03120-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00103-020-03120-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-020-03120-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:06:55Z","timestamp":1615939615000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00103-020-03120-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,17]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["3120"],"URL":"https:\/\/doi.org\/10.1007\/s00103-020-03120-z","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"value":"1436-9990","type":"print"},{"value":"1437-1588","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,17]]},"assertion":[{"value":"17 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.\u00a0Jessen hat in den letzten drei Jahren Beratungshonorare erhalten von: Eli Lilly, Roche, MSD, Biogen, GE Healthcare, Janssen Cliag, AC Immune.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}